Human Genomics of COVID-19 Pneumonia: Contributions of Rare and Common Variants

Annu Rev Biomed Data Sci. 2023 Aug 10:6:465-486. doi: 10.1146/annurev-biodatasci-020222-021705. Epub 2023 May 17.

Abstract

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection is silent or benign in most infected individuals, but causes hypoxemic COVID-19 pneumonia in about 10% of cases. We review studies of the human genetics of life-threatening COVID-19 pneumonia, focusing on both rare and common variants. Large-scale genome-wide association studies have identified more than 20 common loci robustly associated with COVID-19 pneumonia with modest effect sizes, some implicating genes expressed in the lungs or leukocytes. The most robust association, on chromosome 3, concerns a haplotype inherited from Neanderthals. Sequencing studies focusing on rare variants with a strong effect have been particularly successful, identifying inborn errors of type I interferon (IFN) immunity in 1-5% of unvaccinated patients with critical pneumonia, and their autoimmune phenocopy, autoantibodies against type I IFN, in another 15-20% of cases. Our growing understanding of the impact of human genetic variation on immunity to SARS-CoV-2 is enabling health systems to improve protection for individuals and populations.

Keywords: COVID-19 pneumonia; GWAS; SARS-CoV-2; inborn errors of immunity; type I interferons.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19* / genetics
  • Genome-Wide Association Study
  • Genomics
  • Humans
  • Interferon Type I* / genetics
  • SARS-CoV-2 / genetics

Substances

  • Interferon Type I